Efficacy and muscle safety of fluvastatin in cyclosporine-treated cardiac and renal transplant recipients. An exercise provocation test

Transplantation

Volumn 66, Issue 9, 1998, Pages 1175-1181

  Schrama, Yvonne C ^a   Hené, Ronald J ^a   De Jonge, Nicolaas ^a   Joles, Jaap A ^a   Van Rijn, Herman J M ^a   Bär, Dop R ^a   Ververs, Tessa F T ^a   Van Tol, Arie ^b   Koomans, Hein A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; CYCLOSPORIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGLOBIN; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; EXERCISE TEST; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SKELETAL MUSCLE; SLEEP DISORDER;

EID: 0032533413     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199811150-00011     Document Type: Article

References (58)

1. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53.
2. Bittar AE, Ratcliffe PJ, Richardson AJ, et al. The prevalence of hyperlipidemia in renal transplant recipients: associations with immunosuppressive and antihypertensive therapy. Transplantation 1990; 50: 987.
3. Rudas L, Pflugfelder PW, McKenzie FN, Menkis AH, Novick RJ, Kostuk WJ. Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation [see Comments]. Am J Cardiol 1990; 66: 1135.
4. Divakar D, Bailey RR, Frampton CM, George PM, Walmsley TA, Murphy J Hyperlipidemia in stable renal transplant recipients. Nephron 1991; 59: 423.
5. Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. 24th Bethesda conference: cardiac transplantation; Task Force 5: complications. J Am Coll Cardiol 1993; 22: 41.
6. Ong CS, Pollock CA, Caterson RJ, Mahony JF, Waugh DA, Ibels LS. Hyperlipidemia in renal transplant recipients: natural history and response to treatment. Medicine (Baltimore) 1994; 73: 215.
7. Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. J Intern Med 1996; 239: 407.
8. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158.
9. Massy ZA, Guijarro C, Wiederkehr MR, Ma JZ, Kasiske BL. Chronic renal allograft rejection: immunologic and non-immunologic risk factors. Kidney Int 1996; 49: 518.
10. Anonymous. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) [see Comments]. Lancet 1994; 344: 1383.
11. Markell MS, Sumrani N, DiBenedetto A, Friedman EA. Effect of early hyperlipidemia on graft and patient survival in cyclosporine-treated renal transplant patients. Am J Kidney Dis 1993; 22: 233.
12. Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331.
13. Dimeny E, Fellstrom B. Metabolic abnormalities in renal transplant recipients: risk factors and predictors of chronic graft dysfunction? Nephrol Dial Transplant 1997; 12: 21.
14. Yoshimura N, Oka T, Okamoto M, Ohmori Y. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94.
15. Cheung AK, DeVault GA Jr, Gregory MC. A prospective study on treatment of hypercholesterolemia with lovastatin in renal transplant patients receiving cyclosporine. J Am Soc Nephrol 1993; 3: 1884.
16. Holdaas H, Hartmann A, Stenstrom J, Dahl KJ, Borge M, Pfister P. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A.
17. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621.
18. Li PK, Mak TW, Chan TH, Wang A, Lam CW, Lai KN. Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia. Transplantation 1995; 60: 652.
19. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62: 1559.
20. Imagawa DK, Dawson S, Holt CD, et al. Hyperlipidemia after liver transplantation. Transplantation 1996; 62: 934.
21. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use: report of two cases in cardiac transplant recipients. JAMA 1988; 260: 239.
22. East C, Alivizatos PA, Grundy SM. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47.
23. Arellano F, Krupp P. Muscular disorders associated with cyclosporin. Lancet 1991; 337: 915.
24. Berland Y, Vacher Coponat H, Durand C, Baz M, Laugier R, Musso JL. Rhabdomyolysis with simvastatin use [Letter]. Nephron 1991; 57: 365.
25. Horn S, Holzer H, Gasser R, Horina JH. Severe rhabdomyolysis in a kidney-transplant recipient receiving intravenous nifedipine [Letter]. Lancet 1995; 346: 848.
26. Norman DJ, Illingworth DR, Munson J, Hosenpud J Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin [Letter]. N Engl J Med 1988; 318: 46.
27. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62: 28J.
28. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225.
29. Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 1993; 65: 410.
30. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732.
31. Austen JL, Shifrin FA, Bartucci MR, Knauss TC, Schulak JA, Hricik DE. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy. Ann Pharmacother 1996; 30: 1386.
32. Ghods AJ, Milanian I, Arghani H, Ghadiri G. The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients. Transplant Proc 1995; 28: 2579.
33. Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [published erratum appears in Am J Cardiol 1994; 74(6): 639]. Am J Cardiol 1994; 73: 3D.
34. Driessen Kletter MF, Amelink GJ, Bar PR, van Gijn J. Myoglobin is a sensitive marker of increased muscle membrane vulnerability. J Neurol 1990; 237: 234.
35. Herrmann FH, Spiegler A, Wiedemann G. Muscle provocation test: a sensitive method for discrimination between carriers and noncarriers of Duchenne muscular dystrophy. Hum Genet 1982; 61: 102.
36. Bär PR, Amelink GJ, Oldenburg B, Blankenstein MA. Prevention of exercise-induced muscle membrane damage by oestradiol. Life Sci 1988; 42: 2677.
37. Contermans J, Smit JW, Bar PR, Erkelens DW. A comparison of the effects of simvastatin and pravastatin monotherapy on muscle histology and permeability in hypercholesterolaemic patients. Br J Clin Pharmacol 1995; 39: 135.
38. Smit JW, Jansen GH, de Bruin TW, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol 1995; 76: 126A.
39. Smit JW, Wijnne HJ, Schobben F, Sitsen A, de Bruin TW, Erkelens DW. Effects of alcohol consumption on pharmacokinetics, efficacy, and safety of fluvastatin. Am J Cardiol 1995; 76: 89A.
40. Smit JW, Bär PR, Geerdink RA, Erkelens DW. Heterozygous familial hypercholesterolaemia is associated with pathological exercise-induced leakage of muscle proteins, which is not aggravated by simvastatin therapy. Eur J Clin Invest 1995; 25: 79.
41. Bär PR, Amelink GJ. Serum myoglobin after exercise: a useful parameter for the detection of Duchenne carriers. Muscle Nerve 1986; 9: 200.
42. Friedewald WT, Levy RJ. Estimation of the composition of low- density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499.
43. Redgrave TG, Roberts DCK, West E. Separation of plasma lipoproteins by density gradient ultracentrifugation. Anal Biochem 1975; 65: 42.
44. Dullaart RP, Gansevoort RT, Dikkeschei BD, de Zeeuw D, de Jong PE, Van Tol A. Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients. Kidney Int 1993; 44: 91.
45. Hangaard J, Rasmussen O, Norregaard Hansen K, Jorgensen N, Simonsen E, Norgaard-Pedersen B. Early diagnosis of acute myocardial infarction with a rapid latex agglutination test for semi-quantitative estimation of serum myoglobin. Acta med Scand 1987; 221: 343-348.
46. Carruthers SG, Freeman DJ, Koegler JC, Howson W, Keown PA, Laupacis A. Simplified liquid-chromatographic analysis for cyclosporin A and comparison with radioimmunoassay. Clin Chem 1983; 29: 180.
47. Jokubaitis LA, Knopp RH, Frohlich J. Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus. J Intern Med Suppl 1994; 736: 103.
48. Broyles FE, Walden CE, Hunninghake DB, Hill Williams D, Knopp RH. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am J Cardiol 1995; 76: 129A.
49. Tomlinson B, Mak TW, Tsui JY, et al. Effects of fluvastatin on lipid profile and apolipoproteins in Chinese patients with hypercholesterolemia. Am J Cardiol 1995; 76: 136A.
50. Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995; 36: 211.
51. Mann CJ, Yen FT, Grant AM, Bihain BE. Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest 1991; 88: 2059.
52. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-associated inflammatory myopathy [Letter]. N Engl J Med 1992; 327: 649.
53. Deslypere JP, Vermeulen A. Rhabdomyolysis and simvastatin [Letter]. Ann Intern Med 1991; 114: 342.
54. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82: IV281.
55. Reijneveld JC, Koot RW, Bredman JJ, Joles JA, Bär PR. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors of the development of myopathy in young rats. Pediatr Res 1996; 39: 1028.
56. Bhatnagar D, Durrington PN, Neary R, Miller JP. Elevation of skeletal muscle isoform of serum creatine kinase in heterozygous hypercholesterolaemia. J Intern Med 1990; 228: 493.
57. Clarkson PM. Exercise-induced muscle damage: animal and human models. Med Sci Sports Exercise 1992; 24: 510.
58. Borleffs JC, Derksen RH, Bar DP. Serum myoglobin and creatine kinase concentrations in patients with polymyositis or dermatomyositis [Letter]. Ann Rheum Dis 1987; 46: 173.